1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Hospira's filgrastim biosimilar given CHMP nod

 
• By Katie McQue

The EU's CHMP has adopted a positive opinion on Hospira's Nivestim (filgrastim; 12MU/0.2ml, 30MU/0.5mg, 48MU/0.5ml) solution for injection or infusion for the treatment of neutropenia. Nivestim is a biosimilar of Amgen's Neupogen which was the reference product for the application.

The EU's CHMP has adopted a positive opinion on Hospira's Nivestim (filgrastim; 12MU/0.2ml, 30MU/0.5mg, 48MU/0.5ml) solution for injection or infusion for the treatment of neutropenia. Nivestim is a biosimilar of Amgen's Neupogen which was the reference product for the application.

There are already filgrastim biosimilars marketed in various European countries; these include products from Sandoz (Novartis), Teva and Ratiopharm, each...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

More from Therapeutic Category

GSK’s Blenrep US Setback Could Go From Bad To Worse

 
• By Sushmita Panda

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.